Wearable blood pressure device versus home cuff in people with hypertension

Trial details

Who runs it

Aktiia SA

Trial code

NCT05780710

Record updated

5 February 2026

Original description

Study design: Prospective, multicentric, randomized, comparative study Study duration: between 4 and 19 weeks depending on the study group. Population: minimum 35 hypertensives (stage 1 or stage 2) participants divided into 3 groups depending on hypertension criteria. GROUP 1 = untreated hypertensives, stage 1 or stage 2; GROUP 2 = hypertensives, stage 1, who are taking antihypertensive monotherapy; GROUP 3 = hypertensives, stage 1 or stage 2, who are taking antihypertensive treatment that doesn't allow them to have controlled blood pressure.Read full original descriptionShow less

Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake

Study design: Prospective, multicentric, randomized, comparative study Study duration: between 4 and 19 weeks depending on the study group. Population: minimum 35 hypertensives (stage 1 or stage 2) participants divided into 3 groups depending on hypertension criteria. GROUP 1 = untreated hypertensives, stage 1 or stage 2; GROUP 2 = hypertensives, stage 1, who are taking antihypertensive monotherapy; GROUP 3 = hypertensives, stage 1 or stage 2, who are taking antihypertensive treatment that doesn't allow them to have controlled blood pressure.

Device Under Test (DUT): Aktiia device Reference: HBPM (Aktiia cuff) Periods of treatment: For GROUPS 1 and 2, 2 weeks of treatment for each antihypertensive medication followed by a washout period of 2 weeks (3 antihypertensive medications in total with a fixed dose; medication intake order is randomly assigned). For GROUP 3, an individualized new antihypertensive medication will be prescribed during the consultation with the investigator that will be administered for 3 weeks.

Inclusion: Adult subjects aged 21 to 85 years old; Subjects that can read and speak French; Subjects that own a smart phone that uses either the iOS or Android operating system; Hypertensive Stage 1 (SBP 140-159 mmHg or DBP 90-99 mmHg) or Hypertensive Stage 2 (SBP 160-179 mmHg or DBP 100-109 mmHg) or for subjects aged > 65yo SBP ≥160 mmHg,; Naive of antihypertensive drugs at the inclusion in the study (no antihypertensive drugs taken in the last 3 months before Visit 1) and during the conduct of the study apart from the study drugs; Subjects agreeing to attend all 4 on-site visits and follow study procedures; Subjects that have signed the informed consent form.

Exclusion: Subjects have contraindications to the study drugs; Subjects who have received a mastectomy; Subjects with Hypertension Stage 3 (SBP/DBP >180/110 mmHg); Subjects with tachycardia (heart rate at rest > 120bpm); Severe valvular disease; Subjects with diabetes; Subjects with Raynaud's disease; Subjects with an arteriovenous fistula; Subjects with exfoliative skin diseases; For GROUPS 1 and 2 only: Subjects with target organ damage (left ventricular hypertrophy observed on ECG, and/ or, albumin/creatinine ratio in urine ≥3.5 mg/mmol); Subjects with renal dysfunctions (eGFR < 45mL/min/1.73 m2 for patients between 21-85 yo); Low or elevated potassium level: threshold ≤3.5 mmol/L or ≥4.8 mmol/L; Subjects with orthostatic hypotension (a 20 mmHg decrease in systolic BP, or 10 mmHg decrease in diastolic BP when measured in the standing position after a 1-minute waiting period); Subjects who are likely to be unable to perform the HBPM required for the study within the designated time frame (7 to 11; a.m. and 4 to 9 p.m.); Subjects having medical interventions or taking treatments during the study that could have an impact on their BP; Subjects with atrial fibrillation; Cardio myopathy (FE<40%); Implanted devices such as a pacemaker or defibrillator; Subjects with hyper-/hypothyroidism; Subjects with pheochromocytoma; Women in known pregnancy; Subjects with trembling and shivering; Subjects with lymphoedema; Presence of an intravascular device; Subjects with arm paralysis; Subjects with arm amputation; Subjects with upper arm circumference < 22cm or > 42cm; Subjects with wrist circumference > 23cm; Subjects with non-standard circadian rhythm, including shift workers and night workers.

ClinicalTrials.gov NCT05780710